Atlas Venture Opportunity Fund Ii, L.p. - Net Worth and Insider Trading

Atlas Venture Opportunity Fund Ii, L.p. Net Worth

The estimated net worth of Atlas Venture Opportunity Fund Ii, L.p. is at least $13 Million dollars as of 2024-11-05. Atlas Venture Opportunity Fund Ii, L.p. is the 10% Owner of Korro Bio Inc and owns about 195,074 shares of Korro Bio Inc (KRRO) stock worth over $13 Million. Details can be seen in Atlas Venture Opportunity Fund Ii, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Atlas Venture Opportunity Fund Ii, L.p. has not made any transactions after 2024-04-22 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Atlas Venture Opportunity Fund Ii, L.p.

To

Atlas Venture Opportunity Fund Ii, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Atlas Venture Opportunity Fund Ii, L.p. owns 4 companies in total, including Day One Biopharmaceuticals Inc (DAWN) , Disc Medicine Inc (IRON) , and Dyne Therapeutics Inc (DYN) among others .

Click here to see the complete history of Atlas Venture Opportunity Fund Ii, L.p.’s form 4 insider trades.

Insider Ownership Summary of Atlas Venture Opportunity Fund Ii, L.p.

Ticker Comapny Transaction Date Type of Owner
DAWN Day One Biopharmaceuticals Inc 2022-06-17 10 percent owner
IRON Disc Medicine Inc 2022-12-29 10 percent owner
DYN Dyne Therapeutics Inc 2022-12-12 10 percent owner
LIMIT LIMIT 2024-04-22 10 percent owner

Atlas Venture Opportunity Fund Ii, L.p. Latest Holdings Summary

Atlas Venture Opportunity Fund Ii, L.p. currently owns a total of 1 stock. Atlas Venture Opportunity Fund Ii, L.p. owns 195,074 shares of Korro Bio Inc (KRRO) as of April 22, 2024, with a value of $13 Million.

Latest Holdings of Atlas Venture Opportunity Fund Ii, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
KRRO Korro Bio Inc 2024-04-22 195,074 64.87 12,654,450

Holding Weightings of Atlas Venture Opportunity Fund Ii, L.p.


Atlas Venture Opportunity Fund Ii, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Atlas Venture Opportunity Fund Ii, L.p. has made a total of 1 transactions in Korro Bio Inc (KRRO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Korro Bio Inc is the acquisition of 17,857 shares on April 22, 2024, which cost Atlas Venture Opportunity Fund Ii, L.p. around $999,992.

Insider Trading History of Atlas Venture Opportunity Fund Ii, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Atlas Venture Opportunity Fund Ii, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Atlas Venture Opportunity Fund Ii, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Atlas Venture Opportunity Fund Ii, L.p. is -29.25%. GuruFocus also compares Atlas Venture Opportunity Fund Ii, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Atlas Venture Opportunity Fund Ii, L.p. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Atlas Venture Opportunity Fund Ii, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Atlas Venture Opportunity Fund Ii, L.p.

Average Return

No transaction record over 1 Year.

Outperforming Transactions

No transaction record over 1 Year.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -26.59 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -32.51 LIMIT LIMIT LIMIT LIMIT LIMIT

Atlas Venture Opportunity Fund Ii, L.p. Ownership Network

Ownership Network List of Atlas Venture Opportunity Fund Ii, L.p.

No Data

Ownership Network Relation of Atlas Venture Opportunity Fund Ii, L.p.

Insider Network Chart

Atlas Venture Opportunity Fund Ii, L.p. Owned Company Details

What does Day One Biopharmaceuticals Inc do?

Who are the key executives at Day One Biopharmaceuticals Inc?

Atlas Venture Opportunity Fund Ii, L.p. is the 10 percent owner of Day One Biopharmaceuticals Inc. Other key executives at Day One Biopharmaceuticals Inc include Chief Medical Officer Samuel C. Blackman , COO & CFO and Secretary York Charles N Ii , and director & Chief Executive Officer Jeremy Bender .

Day One Biopharmaceuticals Inc (DAWN) Insider Trades Summary

Over the past 18 months, Atlas Venture Opportunity Fund Ii, L.p. made no insider transaction in Day One Biopharmaceuticals Inc (DAWN). Other recent insider transactions involving Day One Biopharmaceuticals Inc (DAWN) include a net sale of 170,555 shares made by Samuel C. Blackman , a net sale of 114,587 shares made by Jeremy Bender , and a net sale of 71,268 shares made by York Charles N Ii .

In summary, during the past 3 months, insiders sold 49,248 shares of Day One Biopharmaceuticals Inc (DAWN) in total and bought 0 shares, with a net sale of 49,248 shares. During the past 18 months, 381,420 shares of Day One Biopharmaceuticals Inc (DAWN) were sold and 2,244,684 shares were bought by its insiders, resulting in a net purchase of 1,863,264 shares.

Day One Biopharmaceuticals Inc (DAWN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Day One Biopharmaceuticals Inc Insider Transactions

No Available Data

Atlas Venture Opportunity Fund Ii, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Atlas Venture Opportunity Fund Ii, L.p.. You might contact Atlas Venture Opportunity Fund Ii, L.p. via mailing address: 300 Technology Square, 8th Floor, Cambridge Ma 02139.